THE TAPE

Alignment Healthcare, Inc. Common Stock

$7.47▲ +1.49%
Last close
Relative strength
2RS
of 99, against every stock▲ +1 on the month
Turning up
Caution
−54.2%
six months against the S&P 500
52-week range
−70.3%
from the high
$6.01$25.12
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +37% on a year ago
Why it is on no screen

ALHC is off the screens on 2 checks.

A base has formed3.4 weeks, from 15.85 to 18.64.
Long enough to count3.4 weeks against 3 needed.
Shallow enough15.0% deep against 35% allowed.
Close to its pivot-59.9% from the pivot; listed down to -20%.
Relative strengthRS 2 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$7.85
+5.1% · tested 3× · last 3 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Alignment Healthcare, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 2, and it sits in Hospital & Medical Service Plans.

Against its industry
CautionBehind its industry over all three, in an industry that is not ahead of the S&P 500.
One month against the S&P 500
-6.9%
Three months against the S&P 500
-41.4%
Six months against the S&P 500
-54.2%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 11.8% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$4.9B
+36.7% year on year
Operating margin
0.9%
Net margin
0.6%
Free cash flow
$77.0M
4.9% of market cap
Price to sales
0.32×
Price to earnings
54.1×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
Growth with the cash to show for it: the quarter confirms the thesis.
Revenue
$1.4B
+1.7% QoQ · +36.7% YoY
Gross margin
—
Net income
−$8.1M
Loss
Free cash flow
$38.6M
Cash generating

What the numbers say

  • Good: Revenue +36.7% year over year, +1.7% on the quarter
  • Weak: Net loss $8M
  • Good: Cash generating: operating cash flow $47M, free cash flow $39M
  • Good: Net cash $403M · cash $728M
Revenue by quarter
Free cash flow
Net income
shares -0.2% in a year · net cash $403.2M

What is not obvious

  • Weak: Interest $4M a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $8M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

No tracked fund holds it now at the end of Q3 2026.

Last quarter: 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-11
+5.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-7.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-05
+10.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-04
+5.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-31
-9.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-10-31
-9.8% on earnings 2026-10-29
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Reported resultsFiling · 2026-10-30
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-10-28
reports 2026-10-29 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy3
Buy6
Hold6
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Alignment Healthcare, Inc. Common Stock (ALHC) — The Tape